Skip to main content

Table 1 Clinical characteristics of patients with de novo metastatic NPC (n = 502)

From: Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein–Barr virus DNA level and tumor response to palliative chemotherapy

 

EBV DNA levels after PCT

Tumor response to PCT

Characteristic

Undetectable

Detectable

P-value

CR/PR

SD/PD

P-value

Total

249

253

 

317

185

 

Gender

 Male

204 (81.9%)

213 (84.2%)

0.552

260 (82.0%)

157 (84.9%)

0.460

 Female

45 (18.1%)

40 (15.8%)

 

57 (18.0%)

28 (15.1%)

 

Age (years)

  ≤ 47

133 (53.4%)

128 (50.6%)

0.533

165 (52.1%)

96 (51.9%)

1.000

  > 47

116 (46.6%)

125 (49.4%)

 

152 (47.9%)

89 (48.1%)

 

T stage

 T1

10 (4.0%)

11 (4.3%)

1.000

10 (3.2%)

11 (5.9%)

0.467

 T2

31 (12.4%)

32 (12.6%)

 

39 (12.3%)

24 (13.0%)

 

 T3

123 (49.4%)

125 (49.4%)

 

161 (50.8%)

87 (47.0%)

 

 T4

85 (34.1%)

85 (33.6%)

 

107 (33.8%)

63 (34.1%)

 

N stage

 N0

13 (5.2%)

3 (1.2%)

0.002

11 (3.5%)

5 (2.7%)

0.790

 N1

53 (21.3%)

36 (14.2%)

 

55 (17.4%)

34 (18.4%)

 

 N2

101 (40.6%)

101 (39.9%)

 

132 (41.6%)

70 (37.8%)

 

 N3

82 (32.9%)

113 (44.7%)

 

119 (37.5%)

76 (41.1%)

 

Metastatic sites

 Bone

130 (52.2%)

96 (37.9%)

< 0.001

157 (49.5%)

69 (37.3%)

< 0.001

 Lung

44 (17.7%)

20 (7.9%)

 

48 (15.1%)

16 (8.6%)

 

 Liver

20 (8.0%)

29 (11.5%)

 

28 (8.8%)

21 (11.4%)

 

 Distant nodal

23 (9.2%)

12 (4.7%)

 

27 (8.5%)

8 (4.3%)

 

 Multiple sites

32 (12.9%)

96 (37.9%)

 

57 (18.0%)

71 (38.4%)

 

PCT regimens

 TPF

77 (30.9%)

53 (20.9%)

0.081

85 (26.8%)

45 (24.3%)

0.639

 TP

59 (23.7%)

62 (24.5%)

 

81 (25.6%)

40 (21.6%)

 

 PF

63 (25.3%)

68 (26.9%)

 

78 (24.6%)

53 (28.6%)

 

 GP

10 (4.0%)

17 (6.7%)

 

18 (5.7%)

9 (4.9%)

 

 Others

40 (16.1%)

53 (20.9%)

 

55 (17.4%)

38 (20.5%)

 

LRRT

 Yes

194 (77.9%)

121 (47.8%)

< 0.001

219 (69.1%)

96 (51.9%)

< 0.002

 No

55 (22.1%)

132 (52.2%)

 

98 (30.9%)

89 (48.1%)

 
  1. Abbreviations: EBV Epstein-Barr virus, PCT palliative chemotherapy, CR complete response, PR partial response, PD disease progression, SD stable disease, TPF cisplatin plus docetaxel plus 5-fluorouracil, TP cisplatin plus docetaxel, PF cisplatin plus 5-fluorouracil, GP cisplatin plus gemcitabine, LRRT locoregional radiotherapy
  2. Undetectable/detectable EBV-DNA levels after PCT is based on a cutoff value of 0 copies per milliliter
  3. P-value was calculated with the Pearson χ2 test